DarwinHealth
Corporate brand
UnclaimedDarwinHealth is a New York biomedical company that combines computational biology, mathematical modeling, and laboratory experiments to discover and prioritize cancer drug targets and treatments.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
DarwinHealth is a United States biomedical company focused on computational oncology and cancer drug discovery. Headquartered in New York, it combines algorithmic analysis of tumor biology with wet-laboratory experiments to identify actionable cancer vulnerabilities, prioritize drug candidates, and support the selection of treatments for individual patients and defined clinical populations. The company was founded in 2015 by Andrea Califano and Gideon Bosker. Their collaboration originated in a 2013 meeting in the British Virgin Islands and was built around research developed in Califano's laboratory at Columbia University. The central premise of DarwinHealth's approach is that cancer cells depend on regulatory proteins and networks that control the activity of many downstream genes. Rather than relying only on the presence or absence of gene mutations, the company's methods seek to infer the functional activity of these regulatory systems from gene-expression data. A major concept associated with the company is the identification of "master regulators"—transcription factors and other proteins that can maintain a tumor's malignant state. In work published in 2016, Califano and Mariano Alvarez described the broader framework of tumor "oncotecture" and analyzed gene-expression data from approximately 20,000 tumor samples spanning 36 tumor types. Their analysis identified roughly 300 candidate master regulators with recurring influence over tumor development. DarwinHealth uses this type of systems-biology analysis to connect tumor-state information with potential therapeutic targets. Its technology portfolio includes the DarwinOncoTarget and DarwinOncoTreat platforms. OncoTarget is intended to identify or prioritize compounds that can affect tumor-relevant master regulators and related molecular dependencies. OncoTreat is oriented toward predicting which existing or investigational therapies may be effective for a particular tumor or patient subgroup. The company also describes a broader DarwinOncoDiscovery drug-discovery methodology that combines tumor checkpoint master-regulator analysis with the selection of appropriate in-vitro and in-vivo models. This is designed to improve preclinical validation and help determine which patients are most suitable for later clinical testing. DarwinHealth has worked with pharmaceutical companies on target discovery, mechanism-of-action analysis, compound prioritization, biomarker identification, and oncology clinical-trial research. Publicly described collaborations include agreements or scientific collaborations with Daiichi Sankyo, Celgene, Bristol Myers Squibb, and Prelude Therapeutics. These relationships have involved applications ranging from the assessment of oncology compound libraries to the discovery of biomarkers for clinical studies. The company's research has also been applied to treatment-response prediction. In work associated with the STORM trial of selinexor and dexamethasone in triple-class-refractory multiple myeloma, DarwinHealth scientists developed a four-protein classifier based on VIPER-assessed protein activity. The classifier distinguished responders from non-responders in the reported analysis and was validated in an independent cohort. Later publications described the protocols behind the DarwinOncoDiscovery platform and further applications of DarwinHealth's computational tools to rare, treatment-resistant, and difficult-to-treat cancers. DarwinHealth is therefore positioned between biotechnology, oncology diagnostics, and pharmaceutical research services. It does not primarily present itself as a conventional consumer healthcare brand. Its business and scientific model centers on using computational models to translate tumor molecular data into drug-development hypotheses, biomarker strategies, and potentially more precise treatment decisions. Publicly available reference material does not establish a stock listing, parent company, ownership structure, or a complete current executive roster.
History
DarwinHealth emerged from the collaboration of biomedical researcher Andrea Califano and entrepreneur Gideon Bosker. The partnership began after the two met in 2013, and the company was established in 2015 in New York. Its scientific foundation was linked to research conducted in the Califano Lab at Columbia University, where computational methods were developed to infer the functional activity of regulatory proteins from gene-expression data. The company's research model addresses a limitation of mutation-centered cancer analysis. A tumor may depend on regulatory proteins even when those proteins are not themselves mutated. DarwinHealth's approach therefore attempts to reconstruct the active regulatory networks that sustain a tumor's phenotype. This work is associated with the concept of oncotection, described in a 2016 Nature Reviews Cancer paper by Andrea Califano and Mariano Alvarez. By examining approximately 20,000 tumor samples across 36 cancer types, the researchers identified about 300 candidate master regulators. These proteins, many of them involved in transcriptional control, were proposed as recurring drivers or maintainers of malignant states. DarwinHealth translated this research into a commercial platform for oncology target discovery and treatment prioritization. Its computational tools analyze tumor gene-expression profiles and use inferred protein activity to connect individual tumors or tumor classes with candidate drug mechanisms. The DarwinOncoTarget platform is directed toward identifying compounds that affect tumor-relevant regulatory dependencies, while DarwinOncoTreat is intended to support predictions about treatment response. The broader DarwinOncoDiscovery methodology combines computational identification of tumor checkpoint master regulators with laboratory testing in selected cellular and animal models. The stated purpose is to improve the quality of preclinical validation and the selection of patients for clinical trials. The company began developing relationships with pharmaceutical partners as its platform matured. In 2018, DarwinHealth and Daiichi Sankyo entered a research collaboration centered on novel cancer targets. In 2019, it worked with Celgene to assess the oncology bioactivity of compounds and to investigate their mechanisms of action against master-regulator proteins. In 2021, Bristol Myers Squibb collaborated with DarwinHealth to examine compounds in its library for possible master-regulator activity. That year, DarwinHealth also worked with Prelude Therapeutics on biomarker identification for oncology trials. A notable application of the company's methods involved multiple myeloma. In research connected with the STORM clinical trial of selinexor and dexamethasone in patients with triple-class-refractory disease, DarwinHealth scientists used VIPER-based protein-activity measurements to construct a classifier involving four proteins: IRF3, ARL2BP, ZBTB17, and ATRX. The reported DarwinOncoMarker analysis separated responders from non-responders and was confirmed in an independent cohort. This work illustrated the company's broader objective of using functional molecular information to identify patients more likely to benefit from a particular therapy. In 2022, DarwinHealth researchers published a Current Protocols article describing the operational methodology of DarwinOncoDiscovery. The protocol emphasized the identification of tumor checkpoint master regulators, the selection of tissue-appropriate in-vitro and in-vivo models, and the use of those models to clarify drug mechanisms. The approach was presented as a way to make preclinical drug development more selective and biologically informative. By 2024, the company was applying its VIPER-related computational methods to tumor gene-expression data and to the analysis of existing and investigational drugs. Public descriptions cited applications in renal carcinoma, gastroenteropancreatic neuroendocrine tumors, breast cancer, prostate cancer, and pancreatic carcinoma, including rare and treatment-resistant settings. Pharmaceutical users, including Bristol Myers Squibb, were reported to have used the technology in the examination of more than 1,500 oncology-related compounds. Reported 2024 findings also included predictions concerning responses to HDAC6 inhibitors in breast cancer and a claimed 91 percent accuracy for DarwinOncoTreat across multiple tumor types. DarwinHealth remains primarily a business-to-business biomedical research and technology company. Its public profile centers on partnerships, computational platforms, scientific publications, and clinical research applications rather than consumer products. Public reference material does not provide confirmed information about a public listing, ticker, parent company, ownership structure, or a full list of current officers.
- 2024
VIPER-based tools applied across oncology settings
[1]DarwinHealth's computational tools were reported in applications involving several cancer types, including rare and treatment-resistant tumors, and the analysis of large oncology compound collections.
- 2022
DarwinOncoDiscovery protocol published
[1]A Current Protocols publication described the methodology used by DarwinOncoDiscovery to connect tumor master regulators with experimental models and drug mechanisms.
- 2021
Bristol Myers Squibb collaboration
[1]Bristol Myers Squibb collaborated with DarwinHealth to explore compounds that could target cancer master regulators.
- 2021
Prelude Therapeutics biomarker collaboration
[1]DarwinHealth and Prelude Therapeutics began a collaboration to identify biomarkers for oncology drug trials.
- 2019
Celgene scientific collaboration
[1]DarwinHealth and Celgene collaborated on prioritizing oncology compound bioactivity and determining mechanisms of action involving master-regulator proteins.
- 2019
DarwinOncoMarker analysis reported in multiple myeloma research
[1]DarwinHealth scientists reported a four-protein VIPER-based classifier associated with response to selinexor and dexamethasone in the STORM multiple myeloma study.
- 2018
Daiichi Sankyo research collaboration
[1]DarwinHealth and Daiichi Sankyo entered a collaboration to identify novel cancer targets.
- 2016
Oncotecture and master-regulator framework described
[1]Andrea Califano and Mariano Alvarez published work describing oncotection and the role of master regulators in maintaining tumor states across cancer types.
- 2015
DarwinHealth founded
[1]DarwinHealth was founded in New York by Andrea Califano and Gideon Bosker as a biomedical company focused on computational cancer research.
- 2013
Founders begin collaboration
[1]Andrea Califano and Gideon Bosker began the collaboration that later led to DarwinHealth after meeting in the British Virgin Islands.
Products and positioning
A computational oncology and biomedical research company that combines systems biology, artificial intelligence, mathematical modeling, and experimental validation to identify cancer dependencies, prioritize therapeutic compounds, and support biomarker-guided drug development.
Computational oncology drug-target discovery
DarwinOncoTarget
DarwinOncoTarget is a computational platform intended to identify and prioritize compounds that act on tumor-relevant molecular dependencies. It uses gene-expression and inferred protein-activity information to evaluate the relationship between drugs and cancer master regulators. The platform is designed for pharmaceutical research, target discovery, compound prioritization, and the investigation of mechanisms of action rather than as a consumer-facing medicine.
Treatment-response prediction
DarwinOncoTreat
DarwinOncoTreat is a computational oncology offering focused on predicting how a tumor or patient subgroup may respond to available or investigational therapies. It analyzes molecular features and inferred regulatory activity to match tumor states with candidate treatments. Public descriptions place it in clinical-trial support, biomarker development, and treatment-stratification workflows, including applications across multiple tumor types.
Cancer drug discovery platform
DarwinOncoDiscovery
DarwinOncoDiscovery is a broader drug-discovery methodology that identifies tumor checkpoint master regulators from patient samples and then selects suitable in-vitro and in-vivo models for testing. Its objective is to connect computationally inferred tumor dependencies with tissue-specific drug mechanisms and more rigorous preclinical validation. The approach is also intended to improve the selection of patients for subsequent clinical studies.
Brand decisions
2021
Deepen use of computational tools in industry and clinical researchStrategyBackground
DarwinHealth's platform was being applied to drug libraries and clinical-trial biomarker questions.
Action taken
The company collaborated with Bristol Myers Squibb on master-regulator activity in compound libraries and with Prelude Therapeutics on oncology-trial biomarkers.
Aftermath
These collaborations broadened the stated application of DarwinHealth's methods across discovery, biomarker development, and clinical research.
2019
Use master-regulator analysis for compound mechanism studiesStrategyBackground
Pharmaceutical oncology programs require ways to prioritize compounds and clarify how they affect tumor biology.
Action taken
DarwinHealth collaborated with Celgene to assess oncology compound bioactivity and investigate mechanisms involving master-regulator proteins.
Aftermath
The work extended the company's platform from target identification toward compound characterization and mechanism-of-action analysis.
2018
Expand into pharmaceutical target-discovery partnershipsOtherBackground
DarwinHealth sought to apply its computational oncology methods beyond academic research and into pharmaceutical cancer research.
Action taken
The company entered a research collaboration with Daiichi Sankyo focused on identifying novel cancer targets.
Aftermath
The collaboration established an early public example of DarwinHealth's partnership-led commercial model.
Recent events
Reported
DarwinHealth and Bristol Myers Squibb announce cancer-target research collaboration[3]
DarwinHealth announced a scientific research collaboration with Bristol Myers Squibb called the Novel Cancer Target Initiative to identify novel cancer targets across tumor subtypes. DarwinHealth will provide proprietary drug-database information and analyses; it will receive an upfront payment and may receive development and commercialization milestone payments.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/darwinhealth-united-states · Editorial policy · How profiles are compiled